These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34003452)

  • 41. Magnitude and relevance of change in health-related quality of life in patients with vascular malformations treated with sirolimus.
    Harbers VEM; Bouwman FCM; van Rijnsoever IMP; Verhoeven BH; van der Vleuten CJM; Schultze Kool LJ; de Laat PCJ; van der Horst CMAM; Kievit W; Te Loo DMWM
    Front Med (Lausanne); 2023; 10():1155476. PubMed ID: 37153086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: A single-center experience.
    Cho YJ; Kwon H; Kwon YJ; Kim SC; Kim DY; Namgoong JM
    J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1488-1494. PubMed ID: 33836285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series.
    Badia P; Ricci K; Gurria JP; Dasgupta R; Patel M; Hammill A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28088. PubMed ID: 31930696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature.
    Bevacqua M; Baldo F; Pastore S; Valencic E; Tommasini A; Maestro A; Rabusin M; Arbo A; Barbi E
    Paediatr Drugs; 2019 Jun; 21(3):185-193. PubMed ID: 31124053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of foam sclerotherapy for treatment of low-flow vascular malformations in children.
    Markovic JN; Nag U; Shortell CK
    J Vasc Surg Venous Lymphat Disord; 2020 Nov; 8(6):1074-1082. PubMed ID: 32284312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
    Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
    Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.
    Adams DM; Trenor CC; Hammill AM; Vinks AA; Patel MN; Chaudry G; Wentzel MS; Mobberley-Schuman PS; Campbell LM; Brookbank C; Gupta A; Chute C; Eile J; McKenna J; Merrow AC; Fei L; Hornung L; Seid M; Dasgupta AR; Dickie BH; Elluru RG; Lucky AW; Weiss B; Azizkhan RG
    Pediatrics; 2016 Feb; 137(2):e20153257. PubMed ID: 26783326
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sirolimus for the treatment of complicated vascular anomalies in children.
    Hammill AM; Wentzel M; Gupta A; Nelson S; Lucky A; Elluru R; Dasgupta R; Azizkhan RG; Adams DM
    Pediatr Blood Cancer; 2011 Dec; 57(6):1018-24. PubMed ID: 21445948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. No Association of Sirolimus with Wound Complications in Children With Vascular Anomalies.
    Mehl SC; Whitlock RS; Ortega RM; Creden S; Iacobas I; Maricevich RS; Rosenberg TL; Rialon KL
    J Pediatr Surg; 2023 Aug; 58(8):1555-1559. PubMed ID: 36599792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medical Treatment of Vascular Anomalies.
    DeMaio A; New C; Bergmann S
    Dermatol Clin; 2022 Oct; 40(4):461-471. PubMed ID: 36243433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA).
    Ozeki M; Asada R; Saito AM; Hashimoto H; Fujimura T; Kuroda T; Ueno S; Watanabe S; Nosaka S; Miyasaka M; Umezawa A; Matsuoka K; Maekawa T; Yamada Y; Fujino A; Hirakawa S; Furukawa T; Tajiri T; Kinoshita Y; Souzaki R; Fukao T
    Regen Ther; 2019 Jun; 10():84-91. PubMed ID: 30705924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sirolimus for vascular anomalies in the first year of life: a systematic review.
    Cavazos R; Patil MS; Gowda SH; Iacobas I; Rosenberg T; Fernandes CJ; Pammi M
    J Perinatol; 2024 Aug; 44(8):1087-1097. PubMed ID: 38245657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiproliferative therapy with sirolimus and propranolol for congenital vascular anomalies in newborns (Case reports).
    Cîrstoveanu C; Bizubac AM; Mustea C; Manolache Ș; Istrate-Bârzan A; Sfrijan D; Marcu V; Iozsa DA; Spătaru RI
    Exp Ther Med; 2021 Oct; 22(4):1097. PubMed ID: 34504551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patient-Reported Outcomes of Bleomycin Sclerotherapy for Low-Flow Vascular Malformations and Predictors of Improvement.
    Horbach SER; van de Ven JS; Nieuwkerk PT; Spuls PI; van der Horst CMAM; Reekers JA
    Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1494-1504. PubMed ID: 29948003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review.
    Nadal M; Giraudeau B; Tavernier E; Jonville-Bera AP; Lorette G; Maruani A
    Acta Derm Venereol; 2016 May; 96(4):448-52. PubMed ID: 26607948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sirolimus in the treatment of kaposiform lymphangiomatosis.
    Zhou J; Yang K; Chen S; Ji Y
    Orphanet J Rare Dis; 2021 Jun; 16(1):260. PubMed ID: 34103076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful outcome with oral sirolimus treatment for complicated lymphatic malformations: a retrospective multicenter cohort study.
    Cho YJ; Kwon H; Ha S; Kim SC; Kim DY; Namgoong JM; Cho MJ; Lee JY; Jung E; Nam SH
    Ann Surg Treat Res; 2024 Mar; 106(3):125-132. PubMed ID: 38435495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sirolimus for the Treatment of a Massive Capillary-Lymphatico-Venous Malformation: A Case Report.
    Vlahovic AM; Vlahovic NS; Haxhija EQ
    Pediatrics; 2015 Aug; 136(2):e513-6. PubMed ID: 26148957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment with oral or topical sirolimus in complex vascular anomalies in pediatrics. Experience in a third-level hospital.
    Fernández Oliveira C; Martínez Roca C; Gómez Tellado M; Salvador Garrido MP; Outeda Macías M; Martín Herranz I
    Cir Pediatr; 2023 Apr; 36(2):60-66. PubMed ID: 37093114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.